Sleep and circadian disturbances are common and often underrecognized non-motor features of progressive supranuclear palsy (PSP). These disturbances significantly impact patient quality of life, caregiver burden, and may provide insights into disease mechanisms.
PSP affects multiple neural systems involved in sleep-wake regulation, including the brainstem, hypothalamus, and subcortical structures. Unlike Parkinson's disease, where REM sleep behavior disorder (RBD) is common, PSP presents with a distinct pattern of sleep abnormalities characterized by early-onset sleep fragmentation, decreased sleep efficiency, and circadian rhythm disturbances.
The sleep-wake cycle disruptions in PSP arise from degeneration of multiple structures:
- Brainstem raphe nuclei: Serotonergic neuron loss affects sleep initiation and maintenance
- Locus coeruleus: Noradrenergic dysfunction disrupts arousal and circadian regulation
- Pedunculopontine nucleus: Cholinergic deficits impair REM sleep generation
- Hypothalamic nuclei: Suprachiasmatic nucleus degeneration disrupts circadian rhythms
- Subthalamic nucleus: Associated with sleep architecture abnormalities
Autonomic dysfunction in PSP compounds sleep disturbances through:
- Thermoregulatory impairments affecting sleep quality
- Cardiovascular dysregulation during sleep transitions
- Blunted circadian variations in heart rate and blood pressure
| Feature |
Description |
Prevalence |
| Reduced total sleep time |
Marked decrease in overall sleep duration |
60-80% |
| Sleep fragmentation |
Frequent awakenings throughout night |
70-90% |
| Decreased sleep efficiency |
Reduced percentage of time in bed spent sleeping |
60-75% |
| Increased sleep latency |
Prolonged time to fall asleep |
40-60% |
| REM sleep abnormalities |
Reduced REM sleep percentage |
30-50% |
- Advanced sleep phase: Tendency to fall asleep and wake earlier
- Irregular sleep-wake pattern: Lack of consistent sleep schedule
- Daytime sleepiness: Excessive somnolence not explained by nighttime sleep
- Reduced circadian amplitude: Weakened distinction between day and night
- Abnormal core body temperature rhythms
- Reduced nighttime temperature drop (normal nocturnal dip absent)
- Impaired sweating responses affecting sleep comfort
- Blunted nocturnal blood pressure dipping
- Reduced heart rate variability
- Impaired baroreflex function during sleep
- Reduced REM sleep latency may be present
- Decreased slow-wave sleep percentages
- Frequent arousals from sleep
- Periodic limb movements may occur
- Core body temperature monitoring
- Melatonin secretion patterns
- Actigraphy for sleep-wake patterns
- Heart rate variability analysis
- Melatonin supplementation: May help restore circadian rhythms
- Wake-promoting agents: Modafinil or methylphenidate for excessive daytime sleepiness
- Low-dose trazodone: Sleep maintenance
- Clonazepam: May help with sleep fragmentation (use with caution due to fall risk)
- Light therapy: Bright light exposure in morning to strengthen circadian rhythms
- Sleep hygiene optimization: Consistent sleep schedule, cool bedroom temperature
- Environmental modifications: Night lights for safety, adaptive equipment
- Caregiver education: Understanding sleep disturbances as disease feature
- Adequate hydration
- Compression stockings for orthostatic issues
- Blood pressure monitoring
- Deceleration capacity of heart rate as marker of autonomic cardiac modulation
- Circadian gene expression in peripheral blood mononuclear cells
- Neuroimaging of sleep-wake centers
Clinical trials targeting sleep and circadian symptoms in PSP face challenges due to:
- Difficulty measuring subjective sleep quality
- Overlap with other non-motor symptoms
- Need for objective outcome measures
Recent studies have identified REM sleep behavior disorder (RBD) as a potential early marker in PSP:
- Overlap syndromes: RBD can precede PSP diagnosis by years
- Synucleinopathy connection: RBD suggests underlying synuclein pathology
- Clinical implications: RBD screening may aid early diagnosis
The 4R tau pathology in PSP affects sleep through specific mechanisms:
- Subthalamic nucleus degeneration: Directly disrupts sleep-wake regulation circuits
- Reticular formation involvement: Impairs arousal mechanisms
- Pedunculopontine nucleus pathology: Affects REM sleep generation
- Basal ganglia sleep architecture: Alters striatal modulation of sleep
flowchart TD
A["4R Tau Pathology"] --> B["Brainstem Degeneration"]
A --> C["Basal Ganglia Dysfunction"]
B --> D["Raphe Nuclei Loss"]
B --> E["Locus Coeruleus Loss"]
B --> F["PPN Pathology"]
C --> G["Striatal Sleep Modulation"]
D --> H["Serotonin Deficiency"]
E --> I["Norepinephrine Deficiency"]
F --> J["REM Sleep Dysfunction"]
G --> K["Sleep Fragmentation"]
H --> K
I --> K
J --> L["REM Sleep Abnormalities"]
K --> M["PSP Sleep Phenotype"]
L --> M
This pathway illustrates how 4R tau pathology in PSP produces the distinctive sleep phenotype characterized by early sleep fragmentation, reduced REM sleep, and circadian rhythm disturbances.
Emerging biomarkers for circadian dysfunction in PSP:
| Biomarker |
Source |
Utility |
| Melatonin |
Saliva/serum |
Circadian phase marker |
| Cortisol rhythm |
Saliva |
HPA axis function |
| Body temperature |
Skin |
Core rhythm |
| Activity monitoring |
Wearable |
Rest-activity patterns |
- Melatonin agonists: Ramelteon for circadian alignment
- Sleep promoters: Low-dose trazodone for insomnia
- Alerting agents: Modafinil for daytime sleepiness
- Light therapy: Morning bright light exposure
- Sleep hygiene: Consistent sleep schedule
- Exercise timing: Morning/afternoon activity
- Suprachiasmatic nucleus integrity on MRI
- Connectivity changes in circadian networks
- Correlation with disease progression
- Routine screening: Include sleep questionnaires in PSP assessments
- Polysomnography: Consider for RBD diagnosis
- Multimodal treatment: Combine pharmacological and behavioral approaches
- Monitoring: Track sleep quality as disease progression marker
The degeneration of sleep-wake regulatory structures in PSP follows the distribution of 4R tau pathology:
| Brain Region |
Tau Burden |
Sleep Effect |
| Pedunculopontine nucleus |
High |
REM sleep loss |
| Dorsal raphe nucleus |
Moderate-high |
Sleep fragmentation |
| Locus coeruleus |
High |
Arousal disruption |
| Suprachiasmatic nucleus |
Moderate |
Circadian misalignment |
| Subthalamic nucleus |
High |
Sleep architecture disruption |
The sleep phenotype in PSP results from multiple neurotransmitter system impairments:
- Cholinergic (PPN): REM sleep generation impaired
- Serotonergic (raphe): Sleep initiation and maintenance disrupted
- Noradrenergic (LC): Arousal regulation abnormal
- GABAergic (ventral pallidum): Sleep-wake transition impaired
- Dopaminergic (SNc/VTA): Circadian modulation disrupted
Polysomnographic findings across sleep stages:
| Stage |
Normal % |
PSP % |
Significance |
| N1 |
5-10% |
15-25% |
Increased sleep latency |
| N2 |
45-55% |
35-45% |
Reduced sleep consolidation |
| N3 |
15-25% |
5-15% |
Deep sleep loss |
| REM |
20-25% |
10-20% |
REM sleep reduction |
Recent studies reveal circadian clock gene dysregulation in PSP:
- BMAL1: Reduced expression in peripheral blood mononuclear cells
- PER2: Phase advance in expression pattern
- CRY1: Altered circadian amplitude
- REV-ERBα: Dysregulated as tau pathology target
Sleep and circadian measures as diagnostic and progression biomarkers:
| Measure |
Diagnostic Utility |
Progression Utility |
| Sleep efficiency |
Moderate |
High |
| REM latency |
Moderate |
Moderate |
| Circadian amplitude |
High |
High |
| Actigraphy patterns |
High |
Very high |
| Melatonin rhythm |
High |
Moderate |
- Tau-modulating agents: May preserve sleep-wake centers
- Orexin receptor antagonists: For insomnia in PSP
- Sodium oxybate: For consolidated sleep in neurodegenerative disease
- Circadian synchronizers: Novel agents targeting clock genes
- Chronotherapy: Timing of activities to align circadian rhythms
- Transcranial magnetic stimulation: Modulating sleep-wake centers
- Optogenetic approaches: Experimental methods for sleep circuit modulation
- Wearable light therapy: Continuous circadian entrainment devices
The relationship between autonomic dysfunction and sleep disruption in PSP:
flowchart TD
A["Tau Pathology in Brainstem"] --> B["Autonomic Centers"]
B --> C["Cardiovascular Dysregulation"]
B --> D["Thermoregulatory Dysfunction"]
C --> E["Nocturnal Hypotension"]
C --> F["HRV Reduction"]
D --> G["Temperature Rhythm Loss"]
D --> H["Sweating Abnormalities"]
E --> I["Sleep Fragmentation"]
F --> I
G --> J["Sleep Quality Reduction"]
H --> J
I --> K["Daytime Dysfunction"]
J --> K
Sleep and circadian dysfunction in PSP compared to other 4R tauopathies:
| Feature |
PSP |
CBD |
MSA |
| Sleep fragmentation |
Severe |
Moderate |
Severe |
| REM behavior disorder |
Uncommon |
Rare |
Very common |
| Circadian dysfunction |
Moderate-severe |
Moderate |
Severe |
| Sleep efficiency |
Reduced |
Moderately reduced |
Severely reduced |
| Daytime sleepiness |
Common |
Less common |
Very common |